Nob Hill Therapeutics, Inc.
Albuquerque, NM · Founded 2016 · CIK 0001690041 · Biotech · Private
Dry powder formulation of 5-azacytidine delivered via novel nebulizer for inhaled lung cancer therapy
nobhilltherapeutics.com →- Grants
- $4.0M
- 5 awards
- Sector median: 1
- Raised
- $2.2M
- 6 Form D · Aug 2024
- 26 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $112,500 | |
| Private capital raised | Form D · SEC | $143,545 | |
| Private capital raised | Form D · SEC | $75,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections | $299,058 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections | $1,158,273 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections | $564,303 | |
| Federal grant | Department of Health and Human Services · Phase II · Aerosolized Epigenetic Therapy for Metastatic Lung Cancer | $861,087 | |
| Private capital raised | Form D · SEC | $1,750,649 | |
| Federal grant | Department of Health and Human Services · Phase II · Aerosolized Epigenetic Therapy for Metastatic Lung Cancer | $1,138,913 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1465 | ANDSON BIOTECH INC. | — | $8.3M |
| 1466 | GC Therapeutics | — | — |
| 1467 | Endogenex, Inc. | — | $122M |
| 1468 | Nob Hill Therapeutics, Inc. | — | $2.2M |
| 1469 | Aptevo Therapeutics Inc. | — | $5.6M |
| 1470 | Up Therapeutics LLC | — | — |
| 1471 | CALIFORNIA STEM CELL INC | — | $1.9M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Paul AtkinsDirector
- R. GoforthDirector
- Robert GoforthDirector
- Noel GreenbergerDirector · Executive Officer
- Chris JappDirector
- Mark KiddExecutive Officer
- Yun LiDirector · Executive Officer
- Jee ShinDirector · Executive Officer
Patents
- Massless Mixing System And Method Of Useapplication
- Massless Mixing System And Method Of Useapplication
- Massless Mixing System And Method Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.